Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 3 19Phase 1 16Phase 1/2 7Phase 4 3Phase EARLY_PHASE1 2Phase NA 1Phase 2/3 1

Status

Recruiting 3Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 4Breast 2Thoracic 1

Conditions

Prostatic Neoplasms 4Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Male Urogenital Diseases 1Genital Diseases, Male 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × darolutamide × Clear all
NCT07190300 2026-05-12

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting
181 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT05367440 2025-12-08

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

CellCentric Ltd.

Phase 1/2 Completed
220 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05272709 2024-05-13

CURATE

Cancer Research UK

Phase 1/2 Recruiting
188 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04737109 2023-11-13

ADDItion

Big Ten Cancer Research Consortium

Phase 1/2 Terminated
6 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT01317641 2017-03-29

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Orion Corporation, Orion Pharma

Phase 1/2 Completed
136 enrolled 28 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡